person · Reporting owner

Berry Lance A

Disclosed activity across 5 companies

Tapewire entity: 23125
SEC CIK: 0001478716

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AEON Biopharma, Inc.PMGM · Entity 7859	Director	February 08, 2021	February 09, 2021
ARTIVION, INC.AORT · Entity 4767	EVP, COO, CFO & Treasurer	August 14, 2026	August 17, 2026
TREACE MEDICAL CONCEPTS, INC.TMCI · Entity 5943	Director	May 19, 2026	May 20, 2026
VAPOTHERM INCVAPO · Entity 87270	Director	September 20, 2024	September 24, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AEON Biopharma, Inc.

Report date February 08, 2021 · Filed February 09, 2021

This filing explicitly reported no securities owned.

ARTIVION, INC.

Report date August 14, 2026 · Filed August 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	210,112	Reported balance After 2026-08-14 transaction · row 1 1 source row Row 1 · 2026-08-14 · Sale · Disposed 715 · Balance 210,112 F1: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction.

TREACE MEDICAL CONCEPTS, INC.

Report date May 19, 2026 · Filed May 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	74,593	Reported balance After 2026-05-19 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-05-19 · Grant · Acquired 30,000 · Balance 74,593 F1: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer. F2: Includes 30,000 restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer.

F2: Includes 30,000 restricted stock units.

VAPOTHERM INC

Report date September 20, 2024 · Filed September 24, 2024

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-09-20 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2024-09-20 · Disposition to issuer · Disposed 22,485 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger, dated as of June 17, 2024, among Veronica Holdings, LLC, Veronica Intermediate Holdings, LLC, Veronica Merger Sub, Inc. and Vapotherm, Inc. (Company), in exchange for a cash payment of $2.18 per share.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-09-20 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2024-09-20 · Disposition to issuer · Disposed 3,000 · Balance 0 F2: The restricted stock unit awards, which these shares were subject to, were canceled in the merger in exchange for a cash payment of $2.18 per underlying share.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.80 · Expires 2030-01-29	Direct	Reported balance After 2024-09-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-09-20 · Disposition to issuer · Disposed 1,781 · Balance 0 F3: This option, which provided for vesting in thirds over three years on January 29, 2021, January 29, 2022 and January 29, 2023, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2032-07-27	Direct	Reported balance After 2024-09-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-09-20 · Disposition to issuer · Disposed 1,089 · Balance 0 F4: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2023 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an Agreement and Plan of Merger, dated as of June 17, 2024, among Veronica Holdings, LLC, Veronica Intermediate Holdings, LLC, Veronica Merger Sub, Inc. and Vapotherm, Inc. (Company), in exchange for a cash payment of $2.18 per share.

F2: The restricted stock unit awards, which these shares were subject to, were canceled in the merger in exchange for a cash payment of $2.18 per underlying share.

F3: This option, which provided for vesting in thirds over three years on January 29, 2021, January 29, 2022 and January 29, 2023, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18.

F4: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2023 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Wright Medical Group N.V.

Report date November 11, 2020 · Filed November 13, 2020

Section 16 reporting ended · disclosed 2020-11-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative	Direct	70,077	Reported balance After 2020-11-11 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-11-11 · Other · Disposed 116,976 · Balance 70,077 F1: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 116,976 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement). F2: Includes 22,584 Shares issuable upon vesting of restricted stock units in respect of Shares (collectively, "Wright RSUs") and 47,493 Shares issuable upon vesting of Wright RSUs granted on July 23, 2020 (the "2020 RSUs"). See note (5) below for the treatment of such Wright RSUs and Wright 2020 RSUs in connection with the Offer.
Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative	Direct	26,227	Reported balance After 2020-11-11 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2020-11-11 · Disposition to issuer · Disposed 43,850 · Balance 26,227 F3: Represents Shares issuable upon vesting of the 2020 RSUs which did not vest at the Acceptance Time and were cancelled and forfeited at the Closing for no Offer Consideration or other consideration. See note (5) below for the treatment of the Wright 2020 RSUs in connection with the Offer. F4: Includes 22,584 Shares issuable upon vesting of the Wright RSUs and 3,643 Shares issuable upon vesting of the 2020 RSUs. See Note (5) below for the treatment of Wright RSUs and Wright 2020 RSUs in connection with the Offer.
Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative	Direct	0	Reported balance After 2020-11-11 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2020-11-11 · Disposition to issuer · Disposed 26,227 · Balance 0 F5: See Exhibit 99.1.
Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative	Direct	61,980	Reported balance After 2020-11-11 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2020-11-11 · Grant · Acquired 61,980 · Balance 61,980 F6: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes.
Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative	Direct	0	Reported balance After 2020-11-11 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2020-11-11 · Disposition to issuer · Disposed 61,980 · Balance 0 F6: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.84 · Expires 2029-07-26	Direct	0	Reported balance After 2020-11-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-11 · Disposition to issuer · Disposed 53,614 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2028-07-24	Direct	0	Reported balance After 2020-11-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-11-11 · Disposition to issuer · Disposed 25,013 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.86 · Expires 2027-07-25	Direct	0	Reported balance After 2020-11-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-11-11 · Disposition to issuer · Disposed 14,125 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.24 · Expires 2026-07-19	Direct	0	Reported balance After 2020-11-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-11-11 · Disposition to issuer · Disposed 10,190 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.06 · Expires 2024-05-13	Direct	0	Reported balance After 2020-11-11 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-11-11 · Disposition to issuer · Disposed 18,262 · Balance 0 F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 116,976 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement).

F2: Includes 22,584 Shares issuable upon vesting of restricted stock units in respect of Shares (collectively, "Wright RSUs") and 47,493 Shares issuable upon vesting of Wright RSUs granted on July 23, 2020 (the "2020 RSUs"). See note (5) below for the treatment of such Wright RSUs and Wright 2020 RSUs in connection with the Offer.

F3: Represents Shares issuable upon vesting of the 2020 RSUs which did not vest at the Acceptance Time and were cancelled and forfeited at the Closing for no Offer Consideration or other consideration. See note (5) below for the treatment of the Wright 2020 RSUs in connection with the Offer.

F4: Includes 22,584 Shares issuable upon vesting of the Wright RSUs and 3,643 Shares issuable upon vesting of the 2020 RSUs. See Note (5) below for the treatment of Wright RSUs and Wright 2020 RSUs in connection with the Offer.

F5: See Exhibit 99.1.

F6: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes.

F7: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 14, 2026 Filed Aug 17, 2026 19:17 UTC	ARTIVION, INC. AORT · Entity 4767	SaleCommon Stock	715	$28.55	$20,412.54	Disclosure SEC source: 0001628280-26-057327 · wk-form4_1786994249.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · EVP, COO, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,112 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document
May 19, 2026 Filed May 20, 2026 01:00 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	GrantCommon Stock	30,000	$0.00	$0.00	Disclosure SEC source: 0001193125-26-231462 · ownership.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,593 F1 · shares: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer. F2 · balance_after: Includes 30,000 restricted stock units. Read SEC document
March 03, 2026 Filed Mar 4, 2026 23:47 UTC	ARTIVION, INC. AORT · Entity 4767	SaleCommon Stock	6,316	$37.78	$238,590.69	Disclosure SEC source: 0001628280-26-014890 · wk-form4_1772668063.xml · nonDerivative · entry 2 Berry Lance A · CIK 0001478716 · EVP, COO, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,827 F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document
March 02, 2026 Filed Mar 3, 2026 19:51 UTC	ARTIVION, INC. AORT · Entity 4767	SaleCommon Stock	5,178	$38.02	$196,892.93	Disclosure SEC source: 0001628280-26-013676 · wk-form4_1772567508.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · EVP, COO, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,269 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document
March 02, 2026 Filed Mar 4, 2026 23:47 UTC	ARTIVION, INC. AORT · Entity 4767	GrantCommon Stock	40,874	$0.00	$0.00	Disclosure SEC source: 0001628280-26-014890 · wk-form4_1772668063.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · EVP, COO, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,143 F1 · shares: Represents performance stock units granted on February 28, 2025. One third (1/3) were issued on March 2, 2026. The remaining shares earned in connection with the February 2025 grant will be eligible to vest and be issued as follows: one third (1/3) on February 28, 2027; and one third (1/3) on February 28, 2028, assuming employment on the relevant vesting date. Read SEC document
February 24, 2026 Filed Feb 25, 2026 22:31 UTC	ARTIVION, INC. AORT · Entity 4767	GrantCommon Stock	37,482	$0.00	$0.00	Disclosure SEC source: 0001628280-26-011825 · wk-form4_1772058711.xml · nonDerivative · entry 3 Berry Lance A · CIK 0001478716 · EVP, COO, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,447 F3 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan. Read SEC document
February 24, 2026 Filed Feb 25, 2026 22:31 UTC	ARTIVION, INC. AORT · Entity 4767	SaleCommon Stock	4,485	$35.69	$160,083.11	Disclosure SEC source: 0001628280-26-011825 · wk-form4_1772058711.xml · nonDerivative · entry 2 Berry Lance A · CIK 0001478716 · EVP, COO, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,965 F2 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document
February 23, 2026 Filed Feb 25, 2026 22:31 UTC	ARTIVION, INC. AORT · Entity 4767	SaleCommon Stock	4,981	$37.59	$187,225.83	Disclosure SEC source: 0001628280-26-011825 · wk-form4_1772058711.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · EVP, COO, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,450 F1 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document
May 20, 2025 Filed May 21, 2025 21:30 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	GrantCommon Stock	23,917	$0.00	$0.00	Disclosure SEC source: 0000950170-25-075893 · ownership.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,593 F1 · shares: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 20, 2026 or (b) the date of the 2026 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer. F2 · balance_after: Includes 24,861 restricted stock units. Read SEC document
March 06, 2025 Filed Mar 10, 2025 21:08 UTC	ARTIVION, INC. AORT · Entity 4767	SaleCommon Stock	4,909	$24.80	$121,763.82	Disclosure SEC source: 0000784199-25-000053 · wk-form4_1741640907.xml · nonDerivative · entry 2 Berry Lance A · CIK 0001478716 · Executive VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,431 F2 · shares: These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document
March 06, 2025 Filed Mar 10, 2025 21:08 UTC	ARTIVION, INC. AORT · Entity 4767	GrantCommon Stock	48,100	$0.00	$0.00	Disclosure SEC source: 0000784199-25-000053 · wk-form4_1741640907.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Executive VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,340 F1 · shares: Represents performance stock units granted on February 23, 2024. One third (1/3) were issued on March 6, 2025. The remaining shares earned in connection with the February 2024 grant will be eligible to vest and be issued as follows: one third (1/3) on February 23, 2026; and one third (1/3) on February 23, 2027, assuming employment on the relevant vesting date. Read SEC document
February 28, 2025 Filed Mar 4, 2025 19:56 UTC	ARTIVION, INC. AORT · Entity 4767	GrantCommon Stock	34,435	$0.00	$0.00	Disclosure SEC source: 0000784199-25-000031 · wk-form4_1741118173.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Executive VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,240 F1 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan. Read SEC document
February 24, 2025 Filed Feb 26, 2025 18:50 UTC	ARTIVION, INC. AORT · Entity 4767	SaleCommon Stock	3,259	$27.31	$88,990.25	Disclosure SEC source: 0000784199-25-000016 · wk-form4_1740595839.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Executive VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,805 F1 · shares: These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. Read SEC document
September 20, 2024 Filed Sep 24, 2024 18:04 UTC	VAPOTHERM INC VAPO · Entity 87270	Disposition to issuerStock Option (right to buy) · Derivative	1,089	$0.00 Strike: $18.48	$0.00	Disclosure SEC source: 0001235802-24-000075 · primary_doc.xml · derivative · entry 4 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,089 shares Expires 2032-07-27 F4 · derivative.exercise_date: This option, which provided for vesting in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2023 annual meeting of stockholders, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18. Read SEC document
September 20, 2024 Filed Sep 24, 2024 18:04 UTC	VAPOTHERM INC VAPO · Entity 87270	Disposition to issuerStock Option (right to buy) · Derivative	1,781	$0.00 Strike: $84.80	$0.00	Disclosure SEC source: 0001235802-24-000075 · primary_doc.xml · derivative · entry 3 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,781 shares Expires 2030-01-29 F3 · derivative.exercise_date: This option, which provided for vesting in thirds over three years on January 29, 2021, January 29, 2022 and January 29, 2023, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Company common stock underlying the option, multiplied by (b) the excess, if any, of $2.18 over the per share exercise price of such option, which cash payment was $0.00 since this option had an exercise price that exceeded $2.18. Read SEC document
September 20, 2024 Filed Sep 24, 2024 18:04 UTC	VAPOTHERM INC VAPO · Entity 87270	Disposition to issuerCommon Stock	3,000	$2.18	$6,540.00	Disclosure SEC source: 0001235802-24-000075 · primary_doc.xml · nonDerivative · entry 2 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: The restricted stock unit awards, which these shares were subject to, were canceled in the merger in exchange for a cash payment of $2.18 per underlying share. Read SEC document
September 20, 2024 Filed Sep 24, 2024 18:04 UTC	VAPOTHERM INC VAPO · Entity 87270	Disposition to issuerCommon Stock	22,485	$2.18	$49,017.30	Disclosure SEC source: 0001235802-24-000075 · primary_doc.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to an Agreement and Plan of Merger, dated as of June 17, 2024, among Veronica Holdings, LLC, Veronica Intermediate Holdings, LLC, Veronica Merger Sub, Inc. and Vapotherm, Inc. (Company), in exchange for a cash payment of $2.18 per share. Read SEC document
May 21, 2024 Filed May 22, 2024 21:30 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	GrantStock Option (Right to Buy) · Derivative	33,260	$0.00 Strike: $4.97	$0.00	Disclosure SEC source: 0000950170-24-063613 · ownership.xml · derivative · entry 2 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,260 Underlying: Common Stock · 33,260 shares Expires 2034-05-21 F3 · derivative.exercise_date: The stock option will vest in 12 substantially equal monthly installments, commencing on June 21, 2024, such that the stock option will be fully vested and exercisable on the earlier of (a) May 21, 2025, or (b) the date of the 2025 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document
May 21, 2024 Filed May 22, 2024 21:30 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	GrantCommon Stock	15,091	$0.00	$0.00	Disclosure SEC source: 0000950170-24-063613 · ownership.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,676 F1 · shares: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 21, 2025 or (b) the date of the 2025 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer. F2 · balance_after: Includes 18,788 restricted stock units. Read SEC document
February 23, 2024 Filed Feb 26, 2024 23:14 UTC	ARTIVION, INC. AORT · Entity 4767	GrantCommon Stock	37,000	$0.00	$0.00	Disclosure SEC source: 0000784199-24-000055 · wk-form4_1708989230.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Executive VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,064 F1 · shares: Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan. Read SEC document
January 01, 2024 Filed Jan 3, 2024 21:17 UTC	VAPOTHERM INC VAPO · Entity 87270	GrantCommon Stock	6,000	$10.00	$60,000.00	Disclosure SEC source: 0001235802-24-000007 · primary_doc.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,485 F1 · shares: Restricted stock unit award granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan in lieu of director cash retainers for 2024. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024. F1 · price: Restricted stock unit award granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan in lieu of director cash retainers for 2024. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024. F2 · balance_after: Includes 8,625 shares that will be issued over time upon the vesting and settlement of restricted stock unit awards. F3 · balance_after: On August 18, 2023, a 1-for-8 reverse split of the common stock of Vapotherm, Inc. occurred resulting in a decrease in the number of shares held by the reporting person. In addition, proportionate adjustments have been made to the reporting person's outstanding equity awards, including the number of restricted stock units as reflected on this Form 4 and described in footnote (2) to this Form 4, to reflect the 1-for-8 reverse stock split. Read SEC document
December 06, 2023 Filed Dec 8, 2023 14:16 UTC	ARTIVION, INC. AORT · Entity 4767	GrantStock Option (Right to Buy) · Derivative	93,633	$0.00 Strike: $17.83	$0.00	Disclosure SEC source: 0000784199-23-000161 · wk-form4_1702044996.xml · derivative · entry 2 Berry Lance A · CIK 0001478716 · Executive VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,633 Underlying: Common Stock · 93,633 shares Expires 2030-12-06 F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. Read SEC document
December 06, 2023 Filed Dec 8, 2023 14:16 UTC	ARTIVION, INC. AORT · Entity 4767	GrantCommon Stock	42,064	$17.83	$750,001.12	Disclosure SEC source: 0000784199-23-000161 · wk-form4_1702044996.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Executive VP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,064 F1 · balance_after: Represents shares of restricted stock that vest on the third anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan. Read SEC document
July 26, 2023 Filed Jul 28, 2023 20:31 UTC	VAPOTHERM INC VAPO · Entity 87270	GrantCommon Stock	21,000	$0.00	$0.00	Disclosure SEC source: 0001235802-23-000079 · primary_doc.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,887 F1 · shares: This restricted stock unit was granted under the 2018 Equity Plan and will vest in full on the earlier of the first anniversary of the date of grant or the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service as a director of the Issuer through the vesting date. F2 · balance_after: Includes 27,000 shares that will be issued over time upon the vesting and settlement of restricted stock unit awards. Read SEC document
May 23, 2023 Filed May 26, 2023 01:00 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	GrantStock Option (Right to Buy) · Derivative	6,305	$0.00 Strike: $26.34	$0.00	Disclosure SEC source: 0001209191-23-032352 · doc4.xml · derivative · entry 2 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,305 Underlying: Common Stock · 6,305 shares Expires 2033-05-23 F3 · derivative.exercise_date: The stock option will vest in 12 substantially equal monthly installments, commencing on June 23, 2023, such that the stock option will be fully vested and exercisable on the earlier of (a) May 23, 2024, or (b) the date of the 2024 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document
May 23, 2023 Filed May 26, 2023 01:00 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	GrantCommon Stock	2,753	$0.00	$0.00	Disclosure SEC source: 0001209191-23-032352 · doc4.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,585 F1 · shares: Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 23, 2024 or (b) the date of the 2024 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer. F2 · balance_after: Includes 5,585 RSUs. Read SEC document
February 10, 2023 Filed Feb 14, 2023 22:47 UTC	VAPOTHERM INC VAPO · Entity 87270	PurchaseWarrant · Derivative	95,238	Not disclosed Strike: $1.17	Not disclosed	Disclosure SEC source: 0001235802-23-000026 · primary_doc.xml · derivative · entry 2 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,238 Underlying: Common Stock · 95,238 shares Expires 2028-02-10 F1 · price: $1.05 per unit, each unit consisted of one share of common stock and a warrant to purchase one share of common stock. Read SEC document
February 10, 2023 Filed Feb 14, 2023 22:47 UTC	VAPOTHERM INC VAPO · Entity 87270	PurchaseCommon Stock	95,238	$1.05	$99,999.90	Disclosure SEC source: 0001235802-23-000026 · primary_doc.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,887 F1 · price: $1.05 per unit, each unit consisted of one share of common stock and a warrant to purchase one share of common stock. F2 · balance_after: Includes 12,000 shares that will be issued over time upon the vesting and settlement of restricted stock unit awards. Read SEC document
January 02, 2023 Filed Jan 4, 2023 23:38 UTC	VAPOTHERM INC VAPO · Entity 87270	GrantCommon Stock	12,000	$2.70	$32,400.00	Disclosure SEC source: 0001235802-23-000011 · primary_doc.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,649 F1 · shares: Restricted stock unit award granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan in lieu of director cash retainers for 2023. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. F1 · price: Restricted stock unit award granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan in lieu of director cash retainers for 2023. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. F2 · balance_after: Includes 12,000 shares that will be issued over time upon the vesting and settlement of restricted stock unit awards. Read SEC document
October 01, 2022 Filed Oct 4, 2022 23:00 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	GrantStock Option (Right to Buy) · Derivative	19,439	$0.00 Strike: $22.07	$0.00	Disclosure SEC source: 0001209191-22-052525 · doc4.xml · derivative · entry 2 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,439 Underlying: Common Stock · 19,439 shares Expires 2032-10-01 F2 · shares: The stock option vests over three years in substantially equal monthly installments with the first vesting to occur on November 1, 2022 such that the stock option will be fully vested and exercisable on October 1, 2025, subject to Reporting Person's providing continued service to Issuer through each vesting date. F2 · derivative.exercise_date: The stock option vests over three years in substantially equal monthly installments with the first vesting to occur on November 1, 2022 such that the stock option will be fully vested and exercisable on October 1, 2025, subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document
October 01, 2022 Filed Oct 4, 2022 23:00 UTC	TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943	GrantCommon Stock	2,832	$0.00	$0.00	Disclosure SEC source: 0001209191-22-052525 · doc4.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,832 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs will vest in three equal yearly installments starting October 1, 2023 such that the RSUs will be fully vested on October 1, 2025 subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document
July 27, 2022 Filed Aug 4, 2022 20:27 UTC	VAPOTHERM INC VAPO · Entity 87270	GrantStock Option (right to buy) · Derivative	8,717	$0.00 Strike: $2.31	$0.00	Disclosure SEC source: 0001235802-22-000084 · primary_doc.xml · derivative · entry 2 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,717 Underlying: Common Stock · 8,717 shares Expires 2032-07-27 F1 · derivative.exercise_date: This option was granted under the Vapotherm, Inc.'s 2018 Equity Incentive Plan (as amended from time to time) and will vest in full on the earlier of the first anniversary of the date of grant or the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service as a director of the Issuer through the vesting date. Read SEC document
May 12, 2022 Filed May 13, 2022 00:57 UTC	VAPOTHERM INC VAPO · Entity 87270	PurchaseCommon Stock	15,673	$3.18	$49,840.14	Disclosure SEC source: 0001235802-22-000061 · primary_doc.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,649 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.185 to $3.19, inclusive. The reporting person undertakes to provide to Vapotherm, Inc., any security holder of Vapotherm, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 5,392 shares that will be issued over time subject to restricted stock units granted under the Vapotherm, Inc. 2018 Equity Incentive Plan. Read SEC document
July 21, 2021 Filed Jul 23, 2021 20:21 UTC	VAPOTHERM INC VAPO · Entity 87270	GrantCommon Stock	5,392	$0.00	$0.00	Disclosure SEC source: 0001235802-21-000084 · primary_doc.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,976 F1 · shares: This annual award in the form of restricted stock units was granted under the Vapotherm, Inc. 2018 Equity Incentive Plan pursuant to the terms of the Vapotherm, Inc. Amended and Restated Non-Employee Director Compensation Policy. The restricted stock units are eligible to vest in full on the earlier of the first anniversary of the date of grant or the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service as a director of the Issuer through the vesting date. F2 · balance_after: Includes 5,392 shares that will be issued over time subject to restricted stock units granted under the Vapotherm, Inc. 2018 Equity Incentive Plan. Read SEC document
November 11, 2020 Filed Nov 13, 2020 17:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	18,262	Not disclosed Strike: $29.06	Not disclosed	Disclosure SEC source: 0001686266-20-000015 · primary_doc.xml · derivative · entry 10 Berry Lance A · CIK 0001478716 · EVP, Chief Fin & Op Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 18,262 shares Expires 2024-05-13 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 17:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	10,190	Not disclosed Strike: $21.24	Not disclosed	Disclosure SEC source: 0001686266-20-000015 · primary_doc.xml · derivative · entry 9 Berry Lance A · CIK 0001478716 · EVP, Chief Fin & Op Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,190 shares Expires 2026-07-19 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 17:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	14,125	Not disclosed Strike: $27.86	Not disclosed	Disclosure SEC source: 0001686266-20-000015 · primary_doc.xml · derivative · entry 8 Berry Lance A · CIK 0001478716 · EVP, Chief Fin & Op Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,125 shares Expires 2027-07-25 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 17:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	25,013	Not disclosed Strike: $24.49	Not disclosed	Disclosure SEC source: 0001686266-20-000015 · primary_doc.xml · derivative · entry 7 Berry Lance A · CIK 0001478716 · EVP, Chief Fin & Op Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 25,013 shares Expires 2028-07-24 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 17:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	53,614	Not disclosed Strike: $27.84	Not disclosed	Disclosure SEC source: 0001686266-20-000015 · primary_doc.xml · derivative · entry 6 Berry Lance A · CIK 0001478716 · EVP, Chief Fin & Op Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 53,614 shares Expires 2029-07-26 F7 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F7 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a "Wright Stock Option") that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time, and at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 17:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerOrdinary Shares, par value EUR 0.03 per share	61,980	$30.75	$1,905,885.00	Disclosure SEC source: 0001686266-20-000015 · primary_doc.xml · nonDerivative · entry 5 Berry Lance A · CIK 0001478716 · EVP, Chief Fin & Op Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F6 · kind: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 17:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantOrdinary Shares, par value EUR 0.03 per share	61,980	$0.00	$0.00	Disclosure SEC source: 0001686266-20-000015 · primary_doc.xml · nonDerivative · entry 4 Berry Lance A · CIK 0001478716 · EVP, Chief Fin & Op Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,980 F6 · kind: In connection with the Offer, each performance share unit in respect of Shares (a "Wright PSU") that was outstanding and unvested immediately prior to the Acceptance Time vested in full at the Acceptance Time, and, at the Closing, was cancelled in exchange for a cash payment equal to the product of (a) $30.75 multiplied by (b) the total number of Shares subject to such Wright PSU as of immediately prior to the Acceptance Time determined based on the maximum achievement of the applicable performance condition, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 17:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerOrdinary Shares, par value EUR 0.03 per share	26,227	$30.75	$806,480.25	Disclosure SEC source: 0001686266-20-000015 · primary_doc.xml · nonDerivative · entry 3 Berry Lance A · CIK 0001478716 · EVP, Chief Fin & Op Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · kind: See Exhibit 99.1. Read SEC document
November 11, 2020 Filed Nov 13, 2020 17:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerOrdinary Shares, par value EUR 0.03 per share	43,850	$0.00	$0.00	Disclosure SEC source: 0001686266-20-000015 · primary_doc.xml · nonDerivative · entry 2 Berry Lance A · CIK 0001478716 · EVP, Chief Fin & Op Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,227 F3 · shares: Represents Shares issuable upon vesting of the 2020 RSUs which did not vest at the Acceptance Time and were cancelled and forfeited at the Closing for no Offer Consideration or other consideration. See note (5) below for the treatment of the Wright 2020 RSUs in connection with the Offer. F4 · balance_after: Includes 22,584 Shares issuable upon vesting of the Wright RSUs and 3,643 Shares issuable upon vesting of the 2020 RSUs. See Note (5) below for the treatment of Wright RSUs and Wright 2020 RSUs in connection with the Offer. Read SEC document
November 11, 2020 Filed Nov 13, 2020 17:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	OtherOrdinary Shares, par value EUR 0.03 per share	116,976	$30.75	$3,597,012.00	Disclosure SEC source: 0001686266-20-000015 · primary_doc.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · EVP, Chief Fin & Op Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,077 F1 · kind: On November 4, 2019, Wright Medical Group N.V. (the "Issuer") entered into a purchase agreement (the "Purchase Agreement") with Stryker Corporation and its subsidiary, Stryker B.V. (the "Purchaser"). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR0.03 per share ("Shares"), of the Issuer (the "Offer"), and, on November 11, 2020 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including 116,976 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement). F2 · balance_after: Includes 22,584 Shares issuable upon vesting of restricted stock units in respect of Shares (collectively, "Wright RSUs") and 47,493 Shares issuable upon vesting of Wright RSUs granted on July 23, 2020 (the "2020 RSUs"). See note (5) below for the treatment of such Wright RSUs and Wright 2020 RSUs in connection with the Offer. Read SEC document
September 02, 2020 Filed Sep 3, 2020 20:01 UTC	VAPOTHERM INC VAPO · Entity 87270	GrantCommon Stock	2,466	$0.00	$0.00	Disclosure SEC source: 0001562180-20-005830 · primarydocument.xml · nonDerivative · entry 2 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,584 F2 · shares: Annual award in the form of shares of common stock pursuant to the Issuer's amended and restated Non-Employee Director Compensation Policy, granted in consideration of the Reporting Person's service on the Issuer's Board of Directors and prorated from his appointment to the Board of Directors on January 29, 2020 through the Issuer's annual meeting on June 23, 2020. Read SEC document
September 01, 2020 Filed Sep 3, 2020 20:01 UTC	VAPOTHERM INC VAPO · Entity 87270	GrantCommon Stock	4,118	$0.00	$0.00	Disclosure SEC source: 0001562180-20-005830 · primarydocument.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,118 F1 · shares: Annual award in the form of restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's amended and restated Non-Employee Director Compensation Policy. This RSU is eligible to vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's 2021 annual meeting of stockholders Read SEC document
August 17, 2020 Filed Aug 19, 2020 16:24 UTC	Wright Medical Group N.V. WMGI · Entity 145358	SaleOrdinary Shares, par value EUR 0.03 per share	4,421	$30.13	$133,226.39	Disclosure SEC source: 0001235802-20-000105 · primary_doc.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · EVP, Chief Finan./Op. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,053 F1 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.13 to $30.135, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · balance_after: Includes 9,510 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 60,567 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document
July 23, 2020 Filed Jul 27, 2020 16:06 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantOrdinary Shares, par value EUR 0.03 per share	47,493	$0.00	$0.00	Disclosure SEC source: 0001235802-20-000082 · primary_doc.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · EVP, Chief Financial & Op. Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,474 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. The grant agreement contemplates that the shares will vest pro rata through the closing of the previously announced Stryker transaction, and shares unvested at closing will be cancelled. F2 · balance_after: Includes 15,631 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 64,925 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document
June 30, 2020 Filed Jul 1, 2020 18:41 UTC	Wright Medical Group N.V. WMGI · Entity 145358	SaleOrdinary Shares, par value EUR 0.03 per share	9,137	$29.63	$270,732.05	Disclosure SEC source: 0001235802-20-000074 · primary_doc.xml · nonDerivative · entry 2 Berry Lance A · CIK 0001478716 · EVP, Chief Finan./Op. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,981 F3 · kind: These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of performance share unit awards. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.61 to $29.654, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · balance_after: Includes 15,631 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 17,432 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document
June 29, 2020 Filed Jul 1, 2020 18:41 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantOrdinary Shares, par value EUR 0.03 per share	21,846	$0.00	$0.00	Disclosure SEC source: 0001235802-20-000074 · primary_doc.xml · nonDerivative · entry 1 Berry Lance A · CIK 0001478716 · EVP, Chief Finan./Op. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,118 F1 · shares: Represents the payout of a performance share unit award for the June 26, 2017 - June 28, 2020 performance period under the Wright Medical Group N.V. 2017 Equity and Incentive Plan, as approved by the Issuer's Compensation Committee of its Board of Directors. Performance share unit awards are paid in ordinary shares of the Issuer. F2 · balance_after: Includes 15,631 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan and 17,432 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.